| http://dbpedia.org/ontology/abstract
|
Briakinumab (ABT-874) is a human monoclona … Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.tibody targets the interleukins 12 and 23.
, Briakinumab (ABT-874) ist ein monoklonaler … Briakinumab (ABT-874) ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung der Schuppenflechte (Psoriasis) vom Pharmaunternehmen Abbott Laboratories entwickelt wurde. Im Januar 2011 wurde der bereits gestellte Zulassungsantrag wieder zurückgezogen.lte Zulassungsantrag wieder zurückgezogen.
, برياكينوماب هو جسم مضاد وحيد النسيلة طورته أبوت ليستخدم في علاج الصداف والتهاب المفاصل الروماتويدي وداء الأمعاء الالتهابي والتصلب اللويحي وداء كرون. يشبه في تأثيره على إنترلوكن 12 و 23.
, Il Briakinumab (o ABT-874) è un anticorpo … Il Briakinumab (o ABT-874) è un anticorpo monoclonale di tipo interamente umano, che viene studiato con studi di fase III per il trattamento di psoriasi, artrite reumatoide, malattie infiammatorie croniche intestinali e sclerosi multipla.Il farmaco agisce sull'interleuchina-12 e 23. Viene sviluppato dalla Abbott.na-12 e 23. Viene sviluppato dalla Abbott.
, Briakinumab (ABT-874) est un anticorps mon … Briakinumab (ABT-874) est un anticorps monoclonal développé par les Laboratoires Abbott pour le traitement de la polyarthrite rhumatoïde, la maladie de Crohn, la rectocolite hémorragique et la sclérose en plaques. En 2011, le développement de ce médicament a été abandonné aux États-Unis et en Europe.été abandonné aux États-Unis et en Europe.
|
| http://dbpedia.org/ontology/casNumber
|
339308-60-0
|
| http://dbpedia.org/ontology/fdaUniiCode
|
978I8M0P8X
|
| http://dbpedia.org/ontology/wikiPageID
|
25230853
|
| http://dbpedia.org/ontology/wikiPageLength
|
6040
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
991684467
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Etanercept +
, http://dbpedia.org/resource/Double-blind +
, http://dbpedia.org/resource/Multiple_sclerosis +
, http://dbpedia.org/resource/Abbott_Laboratories +
, http://dbpedia.org/resource/Inflammatory_bowel_disease +
, http://dbpedia.org/resource/Psoriasis +
, http://dbpedia.org/resource/Cambridge_Antibody_Technology +
, http://dbpedia.org/resource/Ustekinumab +
, http://dbpedia.org/resource/Interleukin +
, http://dbpedia.org/resource/Rheumatoid_arthritis +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Interleukin_12 +
, http://dbpedia.org/resource/Category:AbbVie_brands +
, http://dbpedia.org/resource/Interleukin_23 +
, http://dbpedia.org/resource/Category:Immunosuppressants +
, http://dbpedia.org/resource/Head-to-head_study +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/Humira +
, http://dbpedia.org/resource/Psoriasis_Area_Severity_Index +
, http://dbpedia.org/resource/Crohn%27s_disease +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
|
| http://dbpedia.org/property/atcPrefix
|
L04
|
| http://dbpedia.org/property/atcSuffix
|
AC09
|
| http://dbpedia.org/property/bioavailability
|
N/A
|
| http://dbpedia.org/property/c
|
6376
|
| http://dbpedia.org/property/casNumber
|
339308
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/h
|
9874
|
| http://dbpedia.org/property/legalStatus
|
investigational
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1722
|
| http://dbpedia.org/property/o
|
1992
|
| http://dbpedia.org/property/s
|
44
|
| http://dbpedia.org/property/source
|
u
|
| http://dbpedia.org/property/target
|
IL-12 and IL-23
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
978
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
459982272
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Interleukin_receptor_modulators +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
, http://dbpedia.org/resource/Template:Monoclonal-antibody-stub +
, http://dbpedia.org/resource/Template:Monoclonals_for_immune_system +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Immunosuppressants +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
, http://dbpedia.org/resource/Category:AbbVie_brands +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Briakinumab?oldid=991684467&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Briakinumab +
|
| owl:sameAs |
http://fa.dbpedia.org/resource/%D8%A8%D8%B1%DB%8C%D8%A7%DA%A9%DB%8C%D9%86%D9%88%D9%85%D8%A7%D8%A8 +
, http://it.dbpedia.org/resource/Briakinumab +
, http://de.dbpedia.org/resource/Briakinumab +
, http://yago-knowledge.org/resource/Briakinumab +
, https://global.dbpedia.org/id/3NWWe +
, http://fr.dbpedia.org/resource/Briakinumab +
, http://rdf.freebase.com/ns/m.09ghjv4 +
, http://ar.dbpedia.org/resource/%D8%A8%D8%B1%D9%8A%D8%A7%D9%83%D9%8A%D9%86%D9%88%D9%85%D8%A7%D8%A8 +
, http://dbpedia.org/resource/Briakinumab +
, http://www.wikidata.org/entity/Q3644426 +
|
| rdf:type |
http://dbpedia.org/class/yago/Activity100407535 +
, http://dbpedia.org/class/yago/WikicatExperimentalMedicalTreatments +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Work100575741 +
, http://dbpedia.org/class/yago/Treatment100658082 +
, http://dbpedia.org/class/yago/Care100654885 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://umbel.org/umbel/rc/DrugProduct +
, http://dbpedia.org/class/yago/WikicatAntibodies +
, http://dbpedia.org/class/yago/Event100029378 +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/PsychologicalFeature100023100 +
, http://dbpedia.org/class/yago/Act100030358 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/ontology/ChemicalSubstance +
|
| rdfs:comment |
Briakinumab (ABT-874) ist ein monoklonaler … Briakinumab (ABT-874) ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung der Schuppenflechte (Psoriasis) vom Pharmaunternehmen Abbott Laboratories entwickelt wurde. Im Januar 2011 wurde der bereits gestellte Zulassungsantrag wieder zurückgezogen.lte Zulassungsantrag wieder zurückgezogen.
, Briakinumab (ABT-874) is a human monoclona … Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.tibody targets the interleukins 12 and 23.
, برياكينوماب هو جسم مضاد وحيد النسيلة طورته أبوت ليستخدم في علاج الصداف والتهاب المفاصل الروماتويدي وداء الأمعاء الالتهابي والتصلب اللويحي وداء كرون. يشبه في تأثيره على إنترلوكن 12 و 23.
, Il Briakinumab (o ABT-874) è un anticorpo … Il Briakinumab (o ABT-874) è un anticorpo monoclonale di tipo interamente umano, che viene studiato con studi di fase III per il trattamento di psoriasi, artrite reumatoide, malattie infiammatorie croniche intestinali e sclerosi multipla.Il farmaco agisce sull'interleuchina-12 e 23. Viene sviluppato dalla Abbott.na-12 e 23. Viene sviluppato dalla Abbott.
, Briakinumab (ABT-874) est un anticorps mon … Briakinumab (ABT-874) est un anticorps monoclonal développé par les Laboratoires Abbott pour le traitement de la polyarthrite rhumatoïde, la maladie de Crohn, la rectocolite hémorragique et la sclérose en plaques. En 2011, le développement de ce médicament a été abandonné aux États-Unis et en Europe.été abandonné aux États-Unis et en Europe.
|
| rdfs:label |
Briakinumab
, برياكينوماب
|
